B

Blueprint Medicines Corp
D

BPMC

110.070
USD
6.09
(5.86%)
مغلق
حجم التداول
34,454
الربح لكل سهم
-1
العائد الربحي
-
P/E
-53
حجم السوق
6,992,288,989
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -2.210
    (-1.27%)
    171.520 USD
    AMGN
    AMGN
    2.84
    (1.05%)
    272.25 USD
    BMY
    BMY
    -0.100
    (-0.18%)
    56.300 USD
    GILD
    GILD
    0.150
    (0.16%)
    91.790 USD
    GSK
    GSK
    -0.035
    (-0.10%)
    33.430 USD
    JNJ
    JNJ
    -0.740
    (-0.50%)
    147.060 USD
    LLY
    LLY
    -32.08
    (-4.23%)
    726.07 USD
    MRK
    MRK
    -2.790
    (-2.77%)
    97.940 USD
    PFE
    PFE
    -0.195
    (-0.74%)
    26.305 USD
    REGN
    REGN
    -11.37
    (-1.64%)
    681.49 USD
    VRTX
    VRTX
    4.97
    (1.19%)
    422.10 USD
    المزيد
الأخبار
المقالات

العنوان: Blueprint Medicines Corp

القطاع: Healthcare
الصناعة: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.